News
BioSyngen is developing multiple T-cell immunotherapies with the aim to address a wide range of malignancies.
2023-03-29
The city of Guangzhou welcomes Singapore Prime Minister Lee Hsien Loong, the first stop of his week-...
2023-03-29
The city of Guangzhou welcomes Singapore Prime Minister Lee Hsien Loong, the first stop of his week-long visit to China. Accompanying PM Lee in this trip are Foreign Minister Vivian Balakrishnan, Trad
2023-04-19
April 15, 2023, Biosyngen Pte Ltd (hereinafter as “Biosyngen”) announced that the Company received IND approval for its second product in the pipeline, a T-cell redirection therapy for the treatment o
2023-04-11
April 7th, 2023, Biosyngen Pte Ltd (hereinafter as “Biosyngen”) was granted IND approval by China NMPA for the company’s first-in-class T-cell redirection therapy, it is an autologous T cell therapy f
2023-02-17
February 16th, 2023, Biosyngen Pte Ltd (hereinafter as "Biosyngen") was granted approval by US FDA for the company's IND application for BRG01 cell therapy, path the way for Phase I/II clinical trial. BRG01 is an autologous T cell therapy for relapsed/metastatic nasopharyngeal cancer (NPC) treatment. The prin...
2022-12-14
On Dec. 14th, 2022, Guangzhou Biosyngen Co., Ltd. (hereinafter as “Biosyngen”) made an announcement on the approval granted by the Center for Drug Evaluation (CDE) of China’s National Medical Products
2022-11-16
Biosyngen featured in the “Top 50 Most Innovative Companies of Chinese Biomedicine in 2022”, Pharma BigstarOn November 10th to 11th, 2022, the Shanghai (Minhang) Biopharmaceutical Industry Innovation
2022-10-20
Prof. Jean Paul Thiery, Biosyngen’s Chief Scientist, is ranked among the World’s Top 2% Clinical Scientists 2022Professor Jean Paul Thiery, Biosyngen’s Chief Scientist and Chairman of Scientific Advis
2022-10-21
SINGAPORE, Sept. 28, 2022 /PRNewswire/ — On September 22nd, Biosyngen signed to set up a Cell Therapy GMP Facility which will serve as a bas
2022-09-22
SINGAPORE, Sept. 28, 2022 /PRNewswire/ — On September 22nd, Biosyngen signed to set up a Cell Therapy GMP Facility which will serve as a bas